KT&G Senior Vice President Bang Kyung-Man Recommended as President

News by 2FIRSTS.ai
Feb.23.2024
KT&G Senior Vice President Bang Kyung-Man Recommended as President
KT&G appoints Bang Kyung-Man as final candidate for next CEO, marking first leadership change in 9 years.

According to a report from South Korea's Leading Economic Daily on February 22, the KT&G CEO Candidate Recommendation Committee has decided to recommend Bang Kyung-Man, Senior Vice President, as the final candidate for the next CEO and has submitted the recommendation to the board of directors.

 

Fang Qingwan, the current Senior Vice President and internal director of KT&G, is widely recognized as a strong candidate for the position of future President. He joined the company in 1998 and has held various positions such as head of the global headquarters, head of business departments, and head of strategic planning headquarters.

 

During the meeting on February 16, the committee narrowed down the candidate list to four individuals, including KT&G Senior Vice President Fang Jingman, KGC Ginseng Corporation President Heo Tae-ga, as well as two external candidates, former Samsung Electronics Vice President Kwon Jee-hyun and former AK Holdings Group President Lee Sik-joo. This change in leadership, the first in nine years, will be officially confirmed at the regular shareholder meeting in March.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Tobacco Firm Cabbacis Secures Pod Patent for Low-Nicotine and Industrial Hemp Blends
U.S. Tobacco Firm Cabbacis Secures Pod Patent for Low-Nicotine and Industrial Hemp Blends
U.S. tobacco maker Cabbacis has secured a USPTO patent (No. 12,349,724) for oral vaporizer pods, effective until July 2038. With existing patents, its iBlend™ harm-reduction products—featuring low-nicotine and hemp blends—are now protected in over 30 countries and key global tobacco markets.
Jul.18 by 2FIRSTS.ai
UK store in Wolverhampton loses license for illegal cigarette and alcohol sales
UK store in Wolverhampton loses license for illegal cigarette and alcohol sales
Wolverhampton shop loses license for illegal cigarette and alcohol sales, despite warnings and secret tests.
Aug.13 by 2FIRSTS.ai
Exclusive Interview: How Dholakia Tobacco Built the Rush Brand and Entered the Global Nicotine Pouch Market
Exclusive Interview: How Dholakia Tobacco Built the Rush Brand and Entered the Global Nicotine Pouch Market
Dholakia Tobacco, a 150-year-old Indian tobacco company, is expanding globally with its nicotine pouch brand Rush. At the 2025 World Vape Show, CEO Nihar Dholakia and marketing head Rahoul Naik shared how Rush differentiates through transparent ingredients, lifestyle branding, and adaptive market strategies. Despite regulatory hurdles, the company maintains pharmaceutical-grade standards and is targeting growth in both established and emerging markets.
Jul.11
Caixin Reports: Yiling’s Atomizer Sparks Public Concern as Experts Call for Stronger Oversight
Caixin Reports: Yiling’s Atomizer Sparks Public Concern as Experts Call for Stronger Oversight
Caixin reports that a Yiling Pharmaceutical subsidiary’s atomizer, resembling an e-cigarette, has sparked public concern. Experts classify herbal atomizers as e-cigarettes and call for stricter oversight. China’s tobacco regulator has confirmed such products fall under e-cigarette rules and pledged to maintain strict enforcement.
Jul.31
UK MHRA Releases Database with 329 e-cigarette SKUs, Including Brands like ELFBAR, SKE, OXVA, and INNOKIN
UK MHRA Releases Database with 329 e-cigarette SKUs, Including Brands like ELFBAR, SKE, OXVA, and INNOKIN
The Medicines and Healthcare products Regulatory Agency (MHRA) of the UK announced 329 SKUs in its e-cigarette product notification database between August 2 and August 10, including updates on rechargeable e-cigarettes, open-system e-cigarettes, and multi-flavor pods from brands such as ELFBAR, OXVA, INNOKIN, SKE, and VAPES BARS.
Aug.11 by 2FIRSTS.ai
Non-Nicotine Smoking Cessation Drug Cytisinicline Submitted for FDA Review
Non-Nicotine Smoking Cessation Drug Cytisinicline Submitted for FDA Review
Cytisinicline has been submitted for FDA approval and, if approved, would become the first non-nicotine smoking cessation drug in 20 years.
Jul.07 by 2FIRSTS.ai